Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo

Lilian I. Plotkin, Virginia Lezcano, Jeff Thostenson, Robert S. Weinstein, Stavros C. Manolagas, Teresita Bellido

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Connexin (Cx)43 is required for inhibition of osteocyte and osteoblast apoptosis by bisphosphonates in vitro. Herein, we evaluated its requirement for the in vivo actions of bisphosphonates using mice in which Cx43 was deleted specifically from osteocytes and osteoblasts (Cx43ΔOb_Ot/- mice). Effective removal of Cx43 was confirmed by the presence of the deleted form of the gene and by reduced mRNA and protein expression in osteoblastic cells and bones obtained from Cx43ΔOb_Ot/- mice. The amino-bisphosphonate alendronate (2.3 μmol/kg/d) was injected daily into 5-mo-old female mice (n = 6-11) for 31 days, starting 3 days before implantation of pellets releasing the glucocorticoid prednisolone (2.1 mg/kg/d). Cx43 ΔOb_Ot/- mice and their littermates (Cx43fl/-, Cx43ΔOb_Ot/+, and Cx43fl/+) gained bone with similar kinetics and exhibited identical bone mass from 2 to 4.5 mo of age, indicating that Cx43 deletion from osteocytes and mature osteoblasts does not impair bone acquisition. In addition, prednisolone induced a similar increase in osteocyte and osteoblast apoptosis in Cx43ΔOb_Ot/- or in control Cx43fl/- littermates. However, whereas alendronate prevented prednisolone-induced apoptosis in control Cx43fl/- mice, it was ineffective in Cx43ΔOb_Ot/- mice. In contrast, alendronate inhibited glucocorticoid-induced bone loss in both type of animals, suggesting that inhibition of resorption is the predominant effect of alendronate against the early phase of glucocorticoid-induced bone loss. Taken together with earlier in vitro evidence, these findings show that Cx43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts.

Original languageEnglish (US)
Pages (from-to)1712-1721
Number of pages10
JournalJournal of Bone and Mineral Research
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2008

Fingerprint

Osteocytes
Connexin 43
Diphosphonates
Osteoblasts
Alendronate
Bone and Bones
Prednisolone
Glucocorticoids
Apoptosis
Messenger RNA
Genes

Keywords

  • Apoptosis
  • Bisphosphonates
  • Connexin43
  • Osteoblasts
  • Osteocytes

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. / Plotkin, Lilian I.; Lezcano, Virginia; Thostenson, Jeff; Weinstein, Robert S.; Manolagas, Stavros C.; Bellido, Teresita.

In: Journal of Bone and Mineral Research, Vol. 23, No. 11, 01.11.2008, p. 1712-1721.

Research output: Contribution to journalArticle

@article{4c2dda02e5cd4d51917663bc9051ed8b,
title = "Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo",
abstract = "Connexin (Cx)43 is required for inhibition of osteocyte and osteoblast apoptosis by bisphosphonates in vitro. Herein, we evaluated its requirement for the in vivo actions of bisphosphonates using mice in which Cx43 was deleted specifically from osteocytes and osteoblasts (Cx43ΔOb_Ot/- mice). Effective removal of Cx43 was confirmed by the presence of the deleted form of the gene and by reduced mRNA and protein expression in osteoblastic cells and bones obtained from Cx43ΔOb_Ot/- mice. The amino-bisphosphonate alendronate (2.3 μmol/kg/d) was injected daily into 5-mo-old female mice (n = 6-11) for 31 days, starting 3 days before implantation of pellets releasing the glucocorticoid prednisolone (2.1 mg/kg/d). Cx43 ΔOb_Ot/- mice and their littermates (Cx43fl/-, Cx43ΔOb_Ot/+, and Cx43fl/+) gained bone with similar kinetics and exhibited identical bone mass from 2 to 4.5 mo of age, indicating that Cx43 deletion from osteocytes and mature osteoblasts does not impair bone acquisition. In addition, prednisolone induced a similar increase in osteocyte and osteoblast apoptosis in Cx43ΔOb_Ot/- or in control Cx43fl/- littermates. However, whereas alendronate prevented prednisolone-induced apoptosis in control Cx43fl/- mice, it was ineffective in Cx43ΔOb_Ot/- mice. In contrast, alendronate inhibited glucocorticoid-induced bone loss in both type of animals, suggesting that inhibition of resorption is the predominant effect of alendronate against the early phase of glucocorticoid-induced bone loss. Taken together with earlier in vitro evidence, these findings show that Cx43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts.",
keywords = "Apoptosis, Bisphosphonates, Connexin43, Osteoblasts, Osteocytes",
author = "Plotkin, {Lilian I.} and Virginia Lezcano and Jeff Thostenson and Weinstein, {Robert S.} and Manolagas, {Stavros C.} and Teresita Bellido",
year = "2008",
month = "11",
day = "1",
doi = "10.1359/jbmr.080617",
language = "English (US)",
volume = "23",
pages = "1712--1721",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo

AU - Plotkin, Lilian I.

AU - Lezcano, Virginia

AU - Thostenson, Jeff

AU - Weinstein, Robert S.

AU - Manolagas, Stavros C.

AU - Bellido, Teresita

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Connexin (Cx)43 is required for inhibition of osteocyte and osteoblast apoptosis by bisphosphonates in vitro. Herein, we evaluated its requirement for the in vivo actions of bisphosphonates using mice in which Cx43 was deleted specifically from osteocytes and osteoblasts (Cx43ΔOb_Ot/- mice). Effective removal of Cx43 was confirmed by the presence of the deleted form of the gene and by reduced mRNA and protein expression in osteoblastic cells and bones obtained from Cx43ΔOb_Ot/- mice. The amino-bisphosphonate alendronate (2.3 μmol/kg/d) was injected daily into 5-mo-old female mice (n = 6-11) for 31 days, starting 3 days before implantation of pellets releasing the glucocorticoid prednisolone (2.1 mg/kg/d). Cx43 ΔOb_Ot/- mice and their littermates (Cx43fl/-, Cx43ΔOb_Ot/+, and Cx43fl/+) gained bone with similar kinetics and exhibited identical bone mass from 2 to 4.5 mo of age, indicating that Cx43 deletion from osteocytes and mature osteoblasts does not impair bone acquisition. In addition, prednisolone induced a similar increase in osteocyte and osteoblast apoptosis in Cx43ΔOb_Ot/- or in control Cx43fl/- littermates. However, whereas alendronate prevented prednisolone-induced apoptosis in control Cx43fl/- mice, it was ineffective in Cx43ΔOb_Ot/- mice. In contrast, alendronate inhibited glucocorticoid-induced bone loss in both type of animals, suggesting that inhibition of resorption is the predominant effect of alendronate against the early phase of glucocorticoid-induced bone loss. Taken together with earlier in vitro evidence, these findings show that Cx43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts.

AB - Connexin (Cx)43 is required for inhibition of osteocyte and osteoblast apoptosis by bisphosphonates in vitro. Herein, we evaluated its requirement for the in vivo actions of bisphosphonates using mice in which Cx43 was deleted specifically from osteocytes and osteoblasts (Cx43ΔOb_Ot/- mice). Effective removal of Cx43 was confirmed by the presence of the deleted form of the gene and by reduced mRNA and protein expression in osteoblastic cells and bones obtained from Cx43ΔOb_Ot/- mice. The amino-bisphosphonate alendronate (2.3 μmol/kg/d) was injected daily into 5-mo-old female mice (n = 6-11) for 31 days, starting 3 days before implantation of pellets releasing the glucocorticoid prednisolone (2.1 mg/kg/d). Cx43 ΔOb_Ot/- mice and their littermates (Cx43fl/-, Cx43ΔOb_Ot/+, and Cx43fl/+) gained bone with similar kinetics and exhibited identical bone mass from 2 to 4.5 mo of age, indicating that Cx43 deletion from osteocytes and mature osteoblasts does not impair bone acquisition. In addition, prednisolone induced a similar increase in osteocyte and osteoblast apoptosis in Cx43ΔOb_Ot/- or in control Cx43fl/- littermates. However, whereas alendronate prevented prednisolone-induced apoptosis in control Cx43fl/- mice, it was ineffective in Cx43ΔOb_Ot/- mice. In contrast, alendronate inhibited glucocorticoid-induced bone loss in both type of animals, suggesting that inhibition of resorption is the predominant effect of alendronate against the early phase of glucocorticoid-induced bone loss. Taken together with earlier in vitro evidence, these findings show that Cx43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts.

KW - Apoptosis

KW - Bisphosphonates

KW - Connexin43

KW - Osteoblasts

KW - Osteocytes

UR - http://www.scopus.com/inward/record.url?scp=54249141694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249141694&partnerID=8YFLogxK

U2 - 10.1359/jbmr.080617

DO - 10.1359/jbmr.080617

M3 - Article

C2 - 18597631

AN - SCOPUS:54249141694

VL - 23

SP - 1712

EP - 1721

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 11

ER -